MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN® in Subject With Benign Masseteric Hypertrophy

To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo

Inclusion Criteria:

• subject who aged 20 to less than 65 years
• subject with benign masseteric hypertrophy

Exclusion Criteria:

• subject not appropriate for participating in this study according to the investigator's opinion
• subject with known an anaphylactic response to BoNT/A and other involved ingredients of Investigational product